Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi’s Dellegra Promotion to Home in on Stuffy Nose
January 22, 2013
-
BUSINESS Pfizer Detailing Infectious Disease Portfolios across Divisions
January 21, 2013
-
BUSINESS Drug Makers’ Specialty Care Pipelines Hit Snags in Late-Stage Development
January 21, 2013
-
ORGANIZATION JPMA Bolstering ICH Activities to Propose New Topics from Industry
January 18, 2013
-
BUSINESS Celgene K.K. Focused on MR Training Aiming for No. 1 Ranking Among Hematologists in 2013
January 18, 2013
-
BUSINESS OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
-
BUSINESS Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
-
BUSINESS GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
-
ORGANIZATION JMA Vice Pres. Nakagawa Urges Pharmacies to Rigidly Check Medical Exam History of Epadel OTC Buyers
January 15, 2013
-
REGULATORY Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
-
REGULATORY PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
-
BUSINESS Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
-
BUSINESS AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
-
ORGANIZATION Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
-
BUSINESS “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
-
ORGANIZATION Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
-
ORGANIZATION NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
-
REGULATORY 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
-
REGULATORY LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
-
ORGANIZATION JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…